Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Gilead Sciences, Inc. (GILD) Price & Performance

ARK Autonomous Technology & Robotics ETFTrade

Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

ARK Autonomous Technology & Robotics ETF vs Gilead Sciences, Inc. — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $128.49, while Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while ARK Autonomous Technology & Robotics ETF pays none, and ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

	ARKQ	GILD
Sector	Sector/Thematic	Health
52-Week High	$143.82	$155.80
52-Week Low	$95.28	$110.56
Market Cap	—	$168.35B
Enterprise Value	—	$191.42B
Dividend Yield	—	2.42%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ARKQ

View details →

GILD

Gilead upgrades 2026 sales outlook as HIV drug Biktarvy and Livdelzi show strong growthSeeking Alpha · 2 days agoBullish 2026 National ORBIE Awards honor top CIOs and CISOs across key industry categories in San Jose.Inspire Leadership Network · 4 days agoNeutral View details →

About ARK Autonomous Technology & Robotics ETF

ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.